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ABSTRACT
Advanced Parkinson’s disease (PD) is characterized by the presence of motor 
fluctuations, various degrees of dyskinesia, and disability with functional impact on 
daily living and independence. Therapeutic management aims to extend levodopa 
(L-DOPA) benefit while minimizing motor complications and includes, in selected 
cases, the implementation of drug infusion and surgical techniques. The concept 
of deep brain stimulation (DBS) for PD was introduced over 20 years ago, but our 
understanding of the nuances of this procedure continues to improve. This review 
aims to demonstrate the advances of DBS in the treatment of PD patients.
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Parkinson’s disease (PD) was first described in the 19th century by James 
Parkinson. The disease is neurodegenerative, chronic, and progressive. 
PD is caused by an intense decrease in the production of dopamine, which 
is an important neurotransmitter in the performance of voluntary movements 
of the body automatically, especially in the substantia nigra of the midbrain1.
The disease is characterized by cardinal signs of stiffness, akinesia or 
bradykinesia, tremor and postural instability. Although it presents an idiopathic 
etiology, it is believed that its main triggers come from environmental and 
genetic factors, and may interact to the neurodegenerative development in 
focus. Some cases of PD are accompanied by other comorbidities, such as: 
depression, psychosis, hyposmia, weight loss or dementia. The incidence 
of the disease is approximately 0.15%. There is a higher proportion in the 
population over 60 years old. The aging process is closely intertwined with 
this disorder due to the acceleration of the loss of dopaminergic neurons 
over the years2.
The basal ganglia (BG) are fundamental in understanding the pathophysiology 
of PD. The hyperactivity of the Subthalamic Nucleus (STN) generates several 
of the clinical motor signs of PD. However, if STN is injured, it can also 
increase the risk of developing psychiatric disorders, balism and dyskinesias. 
Another important nucleus in PD is the Globus Pallidus (GP), mainly on the 
internal portion (GPi). Understanding the activity of these two structures and 
their lesions is of paramount importance to neurologists and neurosurgeons3.
There are many pharmacological treatments that are effective to reduce 
the PD symptoms, especially levodopa (L-DOPA). However, the long-term 
motor levodopa-induced adverse effects are very common. Patients with 
advanced PD symptoms can be benefited for surgical procedures, including 
the implantation of electrodes in BG for continuous electric stimulation, 
“deep brain stimulation” (DBS)4. This technique was introduced in the 1990s 
and is accepted as an effective treatment for patients with PD, mainly in the 
advanced stage5.
The extent of benefit is similar for young and old patients, although adverse 
events tend to be higher in older patients. For patients younger than 75 years 
with advanced PD, DBS is more effective than medical therapy in improvement 
of quality of life. DBS allows the reduction of dyskinesia and a better mobility. 
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These improvements positively impact on activities of 
daily living and consequently on emotional well-being. 
DBS also alleviates the disability in patients with 
motor complications secondary to L-DOPA4.
Until 1990, the surgical insertion of the electrodes 
was still very limited. However, this procedure became 
very safe with the microrecording. The microrecording 
is very important to reduce the discrepancy between 
the real anatomical path and the final placement of 
the electrode in the encephalic site of choice. Portions 
often used by neurosurgeons are the dorsal and 
dorsolateral portions of the STN. The DBS technique 
itself has a great advantage, which is reversibility. 
If the results are not demonstrated with the expected 
benefit, the electrodes can be deactivated, without 
any risk to the patients and with a return to the 
pre-operative condition5,6.
Modern DBS for PD was introduced over 20 years 
ago. The surgical technique provided many therapeutic 
benefits for PD patients, but our understanding of 
the nuances of this procedure continues to improve. 
This review summarizes the main advances in DBS 
surgical technique in PD patients and our perspective 
for the future of the procedure.
METHODS AND RESULTS
We conducted a literature review on reliable 
databases (PubMed/MEDLINE, Scielo/LILACS 
and UptoDate) between the years 1960-2018. 
The selection considered the most relevant articles 
unsystematically.
The key terms used were “deep brain stimuation”, 
“previous pallidotomy”, “microrecording”, and “Parkinson 
disease”. A total of 64 papers were included for this 
narrative review.
DISCUSSION
Pharmacological Therapy for PD
L-DOPA is considered the gold standard for 
treating PD motor symptoms, yet tremor response 
to L-DOPA is highly variable among PD patients 
throughout the disease course. Although Parkinsonian 
tremor initially responds to dopaminergic agents in 
a majority of patients, it may become resistant to 
medications as PD progresses. Tremor control often 
comes at the expense of requiring increasing doses 
of medications7.
In treatment with L-DOPA, patients typically 
experience a response to the early stages. However, 
the effect of L-DOPA begins to wear off approximately 
four hours after each dose, leaving patients anticipating 
the need for their next dose. This phenomenon has 
been explained by the observation that dopamine 
nerve terminals are able to store and release 
dopamine early in the course of disease. With the 
increasing degeneration of dopamine terminals, the 
concentration of dopamine in the basal ganglia is 
much more dependent upon plasma L-DOPA levels. 
Plasma levels may fluctuate erratically because of 
the 90-minute half-life of L-DOPA and the frequently 
unpredictable intestinal absorption of this medication7.
The treatment consistency becomes difficult to 
maintain due to the need for frequent adjustments 
to the medication regimen. The response duration 
to L-DOPA shortens over time, which leads to motor 
fluctuations that must be counteracted by higher and 
more frequent doses. In addition, cognitive stress both 
increases the intensity of PD-related tremor and reduces 
the tremor-attenuating effect of L-DOPA, which further 
complicates tremor management. Non-dopaminergic 
circuits may contribute to Parkinsonion tremor and 
constitute an additional therapeutic target for tremor. 
Other medications for managing tremor are less 
effective or associated with intolerable side effects7.
Motor fluctuations are alterations between periods 
of being “on,” during which the patient enjoys a good 
response to medication, and being “off”, during which 
the patient experiences symptoms of the underlying 
Parkinsonism. Dyskinesia usually appears when the 
patient is “on”7,8.
They may occasionally occur in the form of painful 
dystonias when the patient is “off”. It occurs especially 
in the morning on awakening. The dystonic intorsion 
of a foot or curling of the toes (usually on the side 
of greater parkinsonian involvement) occurs as a 
withdrawal reaction because of the long interval 
without medication overnight7,8.
PD therapeutic management aims to extend 
L-DOPA benefit while minimizing motor complications. 
It includes, in selected cases, the implementation 
of drug infusion and surgical techniques. In milder 
forms of motor complications, these can often be 
controlled with manipulation of L-DOPA dose and 
the introduction of supplemental therapies such as 
catechol-O-methyl transferase inhibitors, monoamine 
oxidase B inhibitors, and dopamine agonists including 
apomorphine9.
PD drugs act only on the symptoms of the 
PD and do not prevent its progression. There are 
pharmacological agents in different phases of study. 
These agents aim to improve the treatment of patients 
with PD. Among them, we mention the coenzyme 
Q10, antioxidants, anti-apoptotic agents, N-acetyl 
cysteine, edaravone, glutamate receptor antagonists 
and adenosine A2A receptor antagonists. There are 
other types of emerging treatments for PD, such as 
the use of microRNAs, stem cells and glial-derived 
neurotrophic factor, transglutaminases and vector 
gene therapy10.
http://seer.ufrgs.br/hcpa Clin Biomed Res 2018;38(4) 369
The advances of Deep Brain Stimulation for treatment of Parkinson’s disease
Previous Surgical Techniques for Parkinsonism
In the past, GPi ablation and thalamotomies have 
been widely used as effective and successful options 
for the treatment of PD motor disorders. Currently, 
STN-DBS is the preferred surgical treatment. 
However, despite the good results obtained with 
surgeries, they do not stop the progression of the 
disease. DBS has very great efficacy, but this is 
directly related to the distribution of the tremor, with 
DBS being more effective in the treatment of distal 
appendicular tremors11.
Radiofrequency and radiosurgery pallidotomies 
were initially used to treat tremor symptoms alone. 
These types of lesional procedures have been used 
to some extent in PD patients who decline or are 
poor candidates for DBS. There has been increased 
interest in the use of focused ultrasound (FUS) 
thalamotomies for tremor as it does not require a 
craniotomy and physical brain penetration11.
Successful FUS thalamotomy for essential tremor has 
led investigators to treat highly selected tremor-dominant 
PD patients with FUS thalamotomy when the tremor 
is disabling and FUS subthalamotomy when there is 
an asymmetric disease presentation. While being a 
therapy that does not require an implanted device and 
successive operations for battery changes, lesional 
procedures are not reversible and thus are primarily 
performed unilaterally, limiting its effectiveness in a 
bilateral disease process11,12.
Systematization of the DBS Technique
The DBS technique was introduced in the 1990s 
and is widely accepted as an effective treatment 
technique for patients with PD motor symptoms. 
Until 1990, surgical insertion of the DBS electrodes 
was still very limited due to technical limitations. 
Currently, the procedure is very safe and has a 
great advantage: reversibility. If the results are not 
demonstrated with the expected benefit, the electrodes 
can be deactivated, without any risk to the patients 
and with a return to the preoperative condition13.
Some of the mechanisms of action of the electrodes 
should be mentioned: blockade of sodium channels, 
blockade of synaptic depolarization, point release 
of GABA neurotransmitter and activation of local 
inhibitory neurons in the target nucleus13.
An efficacious STN-DBS imposes a new activity 
pattern within brain circuits, favouring alpha- and 
gamma-like neuronal discharge. This stimulus restores 
the thalamocortical transmission pathway through 
axonal activation. In addition, stimulation via the 
dorsal contacts of the macro-electrode may affect 
cortical activation antidromically. However, basal 
ganglia (BG) modulation remains cardinal for “off’ 
and “on” transition. It is revealed by cGMP increase 
occurring during STN-DBS in the substantia nigra 
pars reticulata and internal globus pallidus13.
Stefani et al.13 hypothesized that STN-DBS will 
improve long-term potentiation (LTP) in motor cortex 
in PD patients. Their findings suggest that STN-DBS 
together with dopaminergic medications can restore 
LTP-like plasticity in motor cortex in PD. Restoration 
of cortical plasticity may be one of the mechanisms 
of how STN-DBS produces clinical benefit.
It is possible that the STN-DBS restores 
striato-centric bidirectional plasticity, and whether 
non-neuronal cellular actions play a part (microglia 
and neurovascular factors). Future studies will 
assess whether extremely anticipated DBS or 
lesioning in selected patients are capable of providing 
neuroprotection to the synuclein-mediated alterations 
of synaptic efficiency13.
Even though the target for DBS consists of gray 
matter structures, DBS predominantly activates the 
axons rather than cell bodies of white matter tracts 
near the deep nuclei, which is of great relevance14. 
The measures of white matter microstructural properties 
and their alterations in various regions of the brain 
have shed light on important aspects of PD-related 
pathological process using diffusion imaging15.
In PD patients, two tracts, namely the 
subthalamo-ponto-cerebellar tract (SPCT) and 
the dentate-thalamic tract (DTT) were identified. 
Sweet et al.16 used probabilistic tractography and 
showed that active contact positions in proximity to 
DTT are associated with tremor improvement during 
the stimulation. Vanegas-Arroyave et al.17 studied 
the tractography patterns of STN-DBS. They used 
probabilistic tractography and showed that from STN 
the areas which are frequently connected with the 
clinically effective contacts included the thalamus, the 
brainstem and the superior frontal gyrus. The strength 
of connectivity to the superior frontal gyrus and 
thalamus correlated with the clinical effectiveness.
Possible Adverse Effects of DBS Technique
After initiation of electrode stimulation, some 
patients may exhibit adverse side effects. With the 
reprogramming of electrode frequency, unwanted 
effects tend to disappear. After initiation of stimulation, 
drug doses tend do decrease as well as the amplitude 
of electrode stimulation18,19.
Some surgical complications can result from 
the implantation of the DBS electrodes, such as: 
intracranial hemorrhages, intracranial hematomas 
and infections. Within this, the overall incidence of 
surgical complications is 2% to 3% (morbidity in 1% 
of patients and mortality in approximately 0.4%)20.
However, confusion, dysarthria and dysphonia 
(3.4%) are the most frequently reported surgical 
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complications in DBS, followed by cognitive and 
psychiatric disorders (2.5 and 1.5%, respectively). 
Other serious complications include intracerebral 
hemorrhage (1.3%) and visual field deficits (0.2%). 
Death (0.1%) rarely occurs (intracerebral hemorrhage 
was significantly associated to the use of recording 
microelectrodes)21.
Selection of Eligible Patient and Preoperative 
Management
Patients should be made fully aware that DBS is 
not able to cure the disease but it is able to optimize 
the motor symptoms, henceforth, the quality of life. 
Second Muthuraman et al.22, the detailed initial 
evaluation is needed preferably in a movement 
disorder center. This support determines whether the 
patient will benefit from DBS. Generally, PD patients 
with intermediate to advanced disease are the most 
selected for the DBS procedure. For this purpose, 
an experienced team of neurologists specialized 
in movement disorders, functional neurosurgeons, 
psychiatrists and psychologists with experience in 
movement disorders needs to be homogenized.
The diagnosis of idiopathic PD should be confirmed, 
as other Parkinson syndromes usually do not respond 
to DBS. According Muthuraman et al.23, patient’s 
current and past antiparkinsonian medication as 
well as the dosing schedule should be carefully 
reviewed. The response to dopaminergic medication 
should be (re) tested as the improvement of motor 
symptoms after the L-DOPA challenge is one of the 
very few known predictors of the clinical outcome 
after DBS. Muthuraman et al.23 relates that there 
is an imperative need for the development of an 
objective and investigator-independent paradigm that 
can accurately denote the symptoms that could be 
targeted by DBS and the approximate improvement 
after the surgery.
Welter et al.24 describe that several clinical 
parameters have been analyzed as possible predictors 
of the post-operative clinical outcome of STN-DBS 
but until now dopaminergic response has been the 
strongest prognostic factor of post-operative outcome. 
The UPDRS score of a patient is assessed in the 
morning after overnight (approximately 12 hours) 
withdrawal of L-DOPA and 20 to 60 minutes after the 
patient has ingested 1.5 times their normal morning 
L-DOPA dose. The best possible ON time is rated as 
ascertained by the patient and the examiner.
Although there is no fixed limit of improvement 
required after the dopaminergic challenge for a DBS 
candidate, motor improvement of at least 30% is an 
objective response criterion. Conventionally, DBS is 
only offered to the patients who fulfill this response 
criterion because only those symptoms which are 
improved by L-DOPA are expected to be improved 
by DBS25.
Schüpbach et al.26 showed that younger patients 
benefited more from the DBS. However, the reason 
why younger patients have better motor outcomes 
after DBS is not clear. One suggested hypothesis was 
that the older patients may have more comorbidities 
and less capacity for neuroplasticity. Probably the 
age of PD patient is a predictor factor of outcome 
after DBS procedure.
Other important clinical criterion for a positive 
DBS response is the cognitive status of the patient. 
The presence of significant cognitive impairment is 
considered a contraindication for STN-DBS. A recent 
study using magnetic resonance imaging (MRI) 
demonstrated that cortical thickness of the frontal 
lobe (paracentral area and superior frontal gyrus) 
predicted the clinical improvement after STN-DBS. 
Baltuch et al.27 demonstrated in patients with cortical 
atrophy of these areas, that a higher stimulation 
voltage was needed for an optimal clinical response. 
For cognitive assessment one of the following tests are 
conventionally used: Mini Mental State Examination 
(MMSE), Montreal Cognitive Assessment (MoCA), 
DemTect, Parkinson Neuropsychometric Dementia 
Assessment (PANDA) or Mini Mental Parkinson 
(MMP)28.
Preoperative Mapping for Insertion of  
Electrodes
Imaging the specific DBS targets and basal ganglia 
circuitry has also become more sophisticated. MRI 
continues to increase in resolution, which improves 
targeting of specific regions of the intended structure 
(STN and GPi). With advances in tractography, it is 
also possible to be able to target output and input 
circuitry as opposed to only the nodes within the 
BG. Not only is diffusion tensor imaging feasible for 
surgical planning of movement disorders, psychiatric 
disorders and pain DBS, but it may also improve 
surgical outcome29.
The advances in imaging techniques, such as 
functional MRI and magnetoencephalography, provide 
tools to better understand connectivity between regions 
of the brain as well as brain activity associated with 
electrical stimulation. This information potentially could 
help in determining better functional and anatomic 
targets for DBS29.
Ricciardi et al.30 proposed the use of MRI in 
3 Tesla (T) for better visualization of the STN-DBS in 
order to reduce the time required for microrecording 
mapping. 3T-MRI can provide less morbidity to the 
patient and greater treatment efficacy.
Cheng et al.31 compared the sequences in 
1.5 T and 3 T, demonstrating an advantage in the 
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observation and analysis of the STN in 3T for patients 
with advanced PD.
A prospective study concluded that both the 
conventional methods of microrecording (conventional 
Zamorano Dujovny frames and the preoperative 
platforms with individual mapping) allow effective and 
safe neurosurgical procedures. There is a lesser time 
of surgery for individual microrecording platforms32.
There are still some limitations in terms of 
effectivity, side-effects, and battery consumption in 
DBS. Not only pathological but also physiological 
neural activity can be suppressed whilst stimulating. 
Adaptive DBS (aDBS) is applied according to the 
level of pathological activity. This method might be 
advantageous. Initial studies of aDBS demonstrate 
effectiveness in PD33.
Many stimulation parameters can be used in aDBS. 
There are two different approaches to the application 
of high frequency aDBS: a binary approach, with 
effective stimulation either on or off, and a scalar 
approach with stimulation voltage being varied up 
to and including therapeutic values. The stimulation 
voltage is not rapidly increased with the induction of 
paresthesia. This issue is particularly important with 
binary on-off stimulation, where it is managed by 
the incorporation of a ramping of stimulation onset 
and offset33.
Preoperative mapping of the specific point of the 
BG to be stimulated is crucial for the DBS outcome. 
The best points of stimulus to STN occur in the dorsal 
and dorsolateral STN borders. Electrode contacts 
used for chronic DBS in PD are placed near the dorsal 
border of the nucleus, a highly cellular region. DBS 
may thus exert its effects by modulating these cells, 
hyperdirect projections from motor cortical areas, 
afferent and efferent fibers to the motor STN34,35.
Clinical Improvement in PD Patients after DBS
DBS is an adjunctive therapy that provides excellent 
tremor control. Patients reflect dramatic improvement 
in their lives following DBS surgery due to reduction 
or abolition of tremor. Tremor before DBS surgery is 
described as pervasive and inescapable. PD patients 
experience intense psychological sequelae as a 
result of prolonged intractable tremor prior to surgery, 
including feelings of embarrassment and shame5.
The DBS is more effective than the best 
pharmacological therapy in alleviating disability in 
patients with moderate or severe PD. The extent 
of benefit is similar for younger and older patients. 
However, adverse events tend to be higher in older 
patients. STN-DBS reduces motor disability and 
improves quality of life in patients with advanced 
PD who have severe L-DOPA-induced motor 
complications5.
There are improvements in motor functions and 
quality of life for many patients with PD after surgery. 
Preoperative levels of catecholamines showed a 
significant correlation with postoperative motor scores 
and quality of life. Yamamoto et al.36 suggest that 
higher levels of pre-operative catecholamine come into 
contact with better results after STN-DBS. According 
to Yamamoto et al.36, catecholamine levels were not 
significantly reduced postoperatively in 11 patients 
despite a significant reduction in equivalent L-DOPA 
doses in treatment. In this study, some patients showed 
increased cerebrospinal levels of homovalinic acid.
Schuepbach et al.37 analyzed the DBS and its benefit 
at an earlier stage of PD. DBS was superior to medical 
therapy with respect to motor disability (P<0.001), 
activities of daily living (P<0.001), L-DOPA-induced 
motor complications (P<0.001), and time with good 
mobility and no dyskinesia (P=0.01). STN-DBS was 
superior to medical therapy in patients with PD and 
early motor complications.
Odekerken et al.38 suggest that STN could be the 
preferred target for DBS in patients with advanced 
PD. There is no large difference in neuropsychological 
outcome between GPi-DBS and STN-DBS after 
12 months33,39.
There have been studies demonstrating the 
long-term efficacy of DBS for PD. The United States 
Veterans Affairs Cooperative study followed patients 
for 2 years, and demonstrated sustained symptom 
improvement and clinical efficacy for both STN-DBS 
and GPi-DBS40.
Stable improvement in motor symptoms, improved 
quality of life measures, and decrease in L-DOPA 
equivalent daily dose have been reported at 4 years 
(STN), 5-6 years (STN and GPi), 6-9 years (STN), 
and 10 years (STN)41-44.
Recent studies demonstrate the benefits of 
STN-DBS in patients with PD45. One meta-analysis 
assessed the long-term efficacy of DBS of the STN 
and GPi for Parkinson disease (PD). According 
to Peng et al.46, STN-DBS and GPi-DBS improve 
motor function and activities of daily living for PD. 
Differences in the long-term efficacy for PD on motor 
symptoms were not observed. Other meta-analysis 
demonstrated that while there was similar individual 
efficacy of STN-DBS and L-DOPA, their combined 
effect on motor severity was additive within and 
beyond 5 years of follow-up47.
Xie et al.48 examined the impacts on individual 
motor subtypes (tremor, rigidity, and gait) between 
STN-DBS and GPi-DBS. They described no 
difference in the motor improvement of these 
patients. Therefore, responsiveness to both STN 
and GPi-DBS was similar among different PD motor 
subtypes. Compared to the GPi-DBS, STN-DBS 
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was more effective for reduction in medication. 
The study reported by Xu et al.49 indicated that 
during the off-medication state, the STN-DBS 
might be superior to GPi-DBS in improving the 
motor function and activities of daily living for PD 
patients. But this study evaluated the short-term 
efficacy of STN-DBS and GPi-DBS.
The study reported by Odekerken et al.50 showed 
more reoperations after GPi-DBS and a significant 
difference was observed. The electrode position of 
the initial surgery was considered optimal, and the 
need for reoperations from GPi-DBS to STN-DBS 
owing to waning effect. Volkmann et al.51 also 
described 4 patients with good initial response to 
GPi-DBS but waning effect that required conversion 
to STN-DBS. This potential adverse event requires 
additional research.
Post-operative Long-term Care Management
Starting the DBS programming sessions a few 
weeks after the implantation allows time for reducing 
the microlesioning effect. Mascia MM describes that 
the stimulation based on constant current are applied 
in severe cases. It makes the stimulation intensity 
independent of the impedance52.
To start the stimulation, the neurologist or 
neurosurgeon performs a primary testing, checking 
the clinical effects and the therapeutic window for 
each of the contacts and the range causing no side 
effects at each electrode contact, keeping the pulse 
and frequency constant. The contact with the best 
clinical benefit/side effects ratio is then activated on 
both sides. The medication therapy is then adapted 
to the stimulation, the most common being the first 
L-DOPA monotherapy53.
The reduction of the L-DOPA needs a cautious 
approach to reach the threshold for best motor 
outcome with no troublesome dyskinesia. If the 
L-DOPA dose is insufficiently reduced, patients might 
develop side effects like dyskinesia or choreiform 
hyperkinetic movements, impulsivity and mania. 
However, reducing L-DOPA too much and too quickly 
might lead to apathy, depression or anhedonia54.
Allert et al.55 suggest that patients need specialized 
neuro-rehabilitation after DBS implantation. Before 
selecting a proper setting of post-surgical rehabilitation, 
the individual needs and goals for rehabilitation 
have to be defined for each DBS patient individually. 
The  goal-specific therapy could be physiotherapy, 
Lee Silverman Voice Treatment (LSVT-BIG) therapy, 
speech therapy, occupational therapy, talk therapy, 
cognitive therapy or behavioral therapy depending 
upon the patient’s need for best long-term clinical 
outcome.
Influence of Previous Ablative Surgery on DBS
There are studies showing that even in patients 
undergoing bilateral pallidotomy, DBS can bring benefits. 
Prior pallidotomy reduces the electrophysiological 
activity of the STN and therefore, its location during 
the operation may become more difficult. In patients 
who have performed previous unilateral pallidotomy, 
DBS is superior in relation to a second pallidotomy. 
Patients who underwent previous ablative surgery 
have lower benefits with DBS than those who did 
not perform prior surgery56,57.
Pallidal stimulation and pallidotomy improve the 
symptoms of PD. However, it is not known which 
modality produces greater benefit in patients who 
have already undergone unilateral pallidotomy. It is 
also suggested that the original pallidal surgery 
provides a greater benefit than subsequent pallidal 
surgery. Pallidal stimulation produces greater 
symptom improvement than a second pallidotomy 
and subsequent surgery did not produce inferior 
results to the original pallidal surgery58,59.
Patients who did not perform prior pallidotomy 
present more benefits in using DBS, evolving with better 
evaluations through of the UPDRS after implantation, 
which therefore places the prior pallidotomy as an 
important aspect to be considered in the indication 
of DBS60-62.
One study included 22 patients who underwent 
STN-DBS. Khabarova et al.63 described that eleven 
patients had undergone prior unilateral pallidotomy 
(n = 6) or VL/VIM thalamotomy (n = 5) while the other 
11 patients had not. The primary outcome was the 
change from baseline in the motor subscore of the 
UPDRS-III 12 months after STN-DBS. Secondary 
outcomes included change in motor response 
complications (UPDRS-IV) and change in L-DOPA 
equivalent daily dose (LEDD).
Khabarova et al.63 demonstrated that in the 
group with prior lesioning UPDRS-III improved by 
45%, from 51.5 ± 9.0% (range, 35-65) to 26.5 ± 8.4 
(range, 21-50) (p < 0.01) and UPDRS-IV by 75%, 
from 8.0 ± 2.01 (range, 5-11) to 2.1 ± 0.74 (range, 1-3) 
(p < 0.01). The  group without prior lesioning UPDRS-III 
improved by 61%, from 74.2% ± 7.32 (range, 63-82) to 
29.3 ± 5.99 (range, 20-42) (p < 0.01) and UPDRS-IV 
by 77%, from 9.1 ± 2.46 (range, 5-12) to 2.0 ± 1.1 
(range, 1-4) (p < 0.01). Comparing the two groups 
(with and without lesioning) no significant differences 
were found either in UPDRS-III (p > 0.05) or UPDRS-IV 
scores (p > 0.05) at 12 months post-DBS.
Khabarova et al.63 demonstrated that the LEDD 
was reduced by 51.4%, from 1008.2 ± 346.4 to 
490.0 ± 194.3 in those with prior surgery (p < 0.01) 
and by 55.0%, from 963.4 ± 96.2 to 433.3 ± 160.2 
in those without (p < 0.01). UPDRS-III improved by 
51.8%, from 53.7 ± 4.6 (range, 50-62) to 25.0 ± 3.8 
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(range, 21-31) in those with prior pallidotomy (p < 0.01), 
and by 37.5%, from 48.8 ± 12.6 (range, 35-65) 
to 29.8 ± 13.6 (range, 22-50) in those with prior 
thalamotomy (p < 0.01). This study indicates that 
bilateral STN-DBS is effective and can be used in 
patients with PD with prior unilateral stereotactic 
destructive operations on subcortical structures.
In patients who performed a previous unilateral 
pallidotomy, the DBS is superior in relation to a second 
pallidotomy. There is still no consensus on the influence 
of unilateral pallidotomy on the electrophysiological 
characteristics of the contralateral STN. STN may 
be intact or intermediate to the ipsilateral side to the 
pallidotomy and a brain without previous palidotomy63.
Ablative Techniques versus DBS Technique in 
The World
Of the neurosurgeons still using ablation on the 
subthalamic nucleus as the surgical treatment of 
PD, approximately 15% use more than one ablative 
technique. The vast majority of neurosurgeons worldwide 
(more than 85%) prefer the DBS technique as the 
best strategy for surgical treatment of Parkinsonism 
in the PD64.
In the last two decades, few studies on DBS 
and PD have been published. Most of the data are 
concentrated in specific subgroups of neurosurgeons, 
mainly from North America and Europe. It should 
be noted that the overall financing for the surgical 
treatment of PD is guaranteed by public investment 
in many countries, but there are still many barriers 
in others countries, like Brazil64.
CONCLUSION
Motor complications can be disabling for PD 
patients. Their management is complex and requires 
experienced assessment to provide the best treatment 
choice. Currently available therapies include drug 
manipulation and surgery. New approaches are being 
investigated, and the number of treatment options is 
increasing. In general, the best results are achieved 
with timely referral to tertiary centers that provide 
appropriate patient screening and selection as well 
as a multidisciplinary approach.
The PD patients should be properly evaluated 
by a multidisciplinary team of movement disorder 
specialists that would ideally include neurologists, 
neurosurgeons, neurophysiologists, psychiatrists, 
neuropsychologists, nurse practitioners, and physical 
therapists. This would also require the ability to 
provide monitoring of efficacy to assess the benefit 
of the various therapies, and specifically to make the 
decision to move from conventional pharmacologic 
treatment to more invasive infusion or surgical 
treatments.
Modern DBS for PD was introduced over 20 years 
ago, but our understanding of the nuances of this 
procedure continues to improve. Despite remarkable 
success in controlling the primary motor symptoms of 
PD, a modeling platform that would predict whether 
STN or GPi stimulation is most likely to provide 
optimal benefit for a given patient does not exist, 
nor have the mechanisms for adverse non-motor 
symptoms been defined.
Nonetheless, expansion of patient selection 
criteria to include younger and older patients and the 
advent of real-time imaging-confirmed DBS electrode 
placement are making this life-changing treatment 
highly effective and available to greater numbers of 
movement disorder patients. Future challenges in 
advancing DBS in PD involve developing a better 
understanding of the intrinsic circuitry of each target, 
which can only come from studies of basal ganglia 
physiology. One of the ultimate goals to be achieved 
with DBS is to maximize efficacy while minimizing 
side effects to PD patients.
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